Upstream Bio Q2 net loss $39.7M; cash $261.3M funds through 2027; Phase 3 on track

Upstream Bio, Inc.

Net loss of $39.7M for Q2 2026 vs $40.0M year ago; R&D spend $36.1M, G&A $7.1M.
Cash and equivalents of $261.3M as of June 30, 2026, expected to fund operations through 2027.
Phase 3 trials in severe asthma and CRSwNP on track to initiate Q1 2027; FDA End-of-Phase 2 meetings on schedule.
Completed enrollment in Phase 2 VENTURE COPD trial (481 participants); data expected H2 2027.
Phase 2 data: ~80% of verekitug-treated CRSwNP patients achieved NPS improvement; ERS late-breaking data Sept 5-9.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.